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Brugada Syndrome: 
Diagnosis and Management
Reza Octavianus, Yoga Yuniadi
Brugada syndro�e associa�ed wi�� �ig� incidence o� sudden dea�� in 
young and o��erwise �eal��y adul�s in �any par�s o� ��e world. T�e Bru-
gada syndro�e w�ic� is c�arac�erized by an �T-seg�en� eleva�ion in ��e 
rig�� precordial ECG leads, is a �a�ilial disease ��a� displays an au�oso�al 
do�inan� �ode o� �rans�ission wi�� inco�ple�e pene�rance. T�e �irs� 
and only gene �o be lin�ed �o Brugada syndro�e is SCN5A, ��e gene ��a� 
encodes �or ��e α subuni� o� ��e cardiac sodiu� c�annel gene. More ��an 
80 �u�a�ions in SCN5A �ave been lin�ed �o ��e syndro�e.
Based on ECG c�arac�eris�ics ��e syndro�e divided in�o ��ree �ypes. Bru-
gada syndro�e is de�ini�ively diagnosed w�en a �ype 1 �T-seg�en� eleva�ion 
is observed in >1 rig�� precordial lead (V1 �o V3) in ��e presence or absence 
o� a sodiu� c�annel– bloc�ing agen�, and in con�unc�ion wi�� one o� ��e 
�ollowing: docu�en�ed ven�ricular �ibrilla�ion (VF), poly�orp�ic ven�ricular 
�ac�ycardia (VT), a �a�ily �is�ory o� sudden cardiac dea�� a� <45 years old, 
coved-�ype ECGs in �a�ily �e�bers, inducibili�y o� VT wi�� progra��ed 
elec�ricals�i�ula�ion, syncope, or noc�urnal agonal respira�ion. Curren�ly, 
an i�plan�able cardiover�er de�ibrilla�or (IC�) is ��e only proven e��ec�ive 
�rea��en� �or ��e disease.
(J Kardiol Indones. 2012;33:113-26)
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Sindrom Brugada menyebabkan insiden kematian mendadak yang tinggi pada orang muda yang normal secara fisik. Sindrom 
Brugada yang ditandai dengan elevasi segmen ST di sadapan prekordial kanan merupakan suatu penyakit familial dengan trans-
misi autosomal dominan yang tidak lengkap.  The first and only gene to be linked to Brugada syndrome is SCN5A merupakan 
gen yang pertama diketahui dan juga satu-satunya yang berkaitan dengan sindrom Brugada. Gen ini melakukan encoding 
subunit α dari gen kanal natrium jantung. Terdapat lebih dari 80 mutasi SCN5A yang berkaitan dengan sindrom Brugada. 
Berdasarkan karakteristik EKG, sindrom Brugada dibagi menjadi 3 tipe. Diagnosis pasti sindrom Brugada ditegakkan bila 
didapatkan gambaran EKG tipe 1 yaitu elevasi segmen ST di V1 sampai V3 baik dalam keadaan dengan atau tanpa obat 
penghambat kanal kalsium, disertai adanya salah satu berikut ini: VF terdokumentasi, VT polimorfik, riwayat keluarga dengan 
kematian jantung mendadak pada usia kurang dari 45 tahun, gambarn EKG coved pada anggota keluarga, terinduksi VT pada 
stimulasi elektrik, sinkop, atau adanya respirasi agonal nokturna. Saat ini ICD merupakan satu-satunya terapi yang terbukti 
efektif untuk sindrom ini. 
(J Kardiol Indones. 2012;33:113-26)
Kata kunci:  sindrom Brugada, tinjauan pustaka
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Since its introduction as a clinical entity in 1992, the 
Brugada syndrome has attracted great interest because 
of its high incidence in many parts of the world and its 
association with high risk for sudden death in young 
and otherwise healthy adults and, less frequently, in 
infants and children. In recent years, an exponential 
rise in the number of reported cases and a striking 
proliferation of articles defining the clinical, genetic, 
cellular, ionic, and molecular aspects of the disease 
have occurred.1,2
A number of ambiguities exist concerning the 
diagnosis of Brugada syndrome. The electrocar-
diographic signature of the syndrome is dynamic 
and often concealed,3 so it is difficult to estimate 
the true prevalence of the disease in the general 
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population.4 Normalization of the ECG signature 
of this syndrome by whatever mechanism may lead 
to an underestimation of the prevalence of the 
disease, thus placing some patients at risk. It is, 
therefore, of some importance to identify whether 
patients with the concealed versus overt syndrome 
are at similar risks for arrhythmic events and, if so, 
to identify an approach to unmask those cases that 
are concealed.5
Polymorphic ventricular tachycardia (VT) and 
ventricular fibrillation (VF) developing in patients 
with structurally normal hearts accounts for 5% to 
12% of the >300 000 sudden deaths of Americans 
each year. Approximately half of these are attributed 
to the Brugada syndrome.6
Clinical Characteristics and 
Epidemiology
The Brugada syndrome is characterized by an ST-
segment elevation in the right precordial ECG leads 
and a high incidence of sudden death in patients with 
structurally normal hearts and unrelated to ischemia, 
electrolyte imbalance.3 The syndrome typically mani-
fests during adulthood, with a mean age of sudden 
death of 41±15 years. The youngest patient clinically 
diagnosed with the syndrome is 2 days old and the 
oldest is 84 years old. The syndrome is estimated to 
be responsible for at least 4% of all sudden deaths 
and at least 20% of sudden deaths in patients with 
structurally normal hearts. The prevalence of the 
disease is estimated to be 5/10 000 inhabitants and, 
apart from accidents, is the leading cause of death 
in men < 40 years old, particularly in countries in 
which the syndrome is endemic.4  Because the ECG 
is so dynamic and often concealed, it is difficult to 
estimate the true incidence of the disease in the gen-
eral population.
The Brugada syndrome is a familial disease that 
displays an autosomal dominant mode of transmis-
sion with incomplete penetrance, most diagnosed in 
males (8:1 ratio of males:females) of Asian origin.7  
The syndrome occurs more commonly in Southeast 
Asians, with the highest incidence occurring in the 
peoples of Nothern Thailand. The prevalence of the 
Brugada syndrome among the general population in 
Europe and the United States is thought to be much 
lower, although among Southeast Asian immigrants it 
may be as high as it is in Southeast Asia itself.8.9
Genetic Factors Underlying The 
Brugada Syndrome
 
Inheritance of Brugada syndrome occurs via an auto-
somal dominant mode of transmission, so offspring 
of people with the mutant gene have a 50% chance of 
inheriting it from their affected  parent. The first and 
only gene to be linked to Brugada syndrome is SCN5A, 
the gene that encodes for the α subunit of the cardiac so-
dium channel gene. More than 80 mutations in SCN5A 
have been linked to the syndrome since 2001.10
About two dozen of the these mutations have been 
studied in expression systems and shown to result 
in loss of function due either to: (1) a failure of the 
sodium channel to express, (2) a shift in the voltage- 
and time-dependence of INa activation, inactivation, 
or reactivation, (3) an entry of the sodium channel 
into an intermediate state of inactivation from which 
it recovers more slowly, (4) an accelerated inactivation 
of the sodium channel SCN5A mutations account for 
approximately 18-30% of Brugada syndrome cases. 
A higher incidence of SCN5A mutations has been 
reported in familial than in sporadic cases.11 Of note, 
negative SCN5A results generally do not rule out causal 
gene mutations, since in general the promoter region, 
cryptic splicing mutations or presence of gross rear-
rangements is not part of routine investigation.12
Based on findings to date, knowledge of a specific 
mutation may not provide guidance in formulating a 
diagnosis or determining a prognosis. Mutations have 
been reported throughout the SCN5A gene, and it is 
not as yet clear which of these if any are associated with a 
greater risk of arrhythmic events or sudden death. Genetic 
testing is recommended for support of the clinical diag-
nosis, for early detection of relatives at potential risk, 
and particularly for the purpose of advancing research 
and consequently our understanding of genotype–
phenotype relations.12
 
Types Of Brugada Syndrome
Three ECG repolarization patterns in the right pre-
cordial leads are recognized : 3 (1) Type 1 is diagnostic 
of Brugada syndrome and is characterized by a coved 
ST-segment elevation  ≥ 2 mm (0.2 mV) followed by a 
negative T wave, (2) Type 2 ST-segment elevation has a 
saddleback appearance with a high takeoff ST-segment 
elevation of ≥ 2 mm, a trough displaying  ≥1 mm ST 
elevation, and then either a positive or biphasic T wave, 
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(3) Type 3 has either a saddleback or coved appearance 
with an ST-segment elevation of  <1 mm (Figure 1).
Type 2 and type 3 ECG are not diagnostic of the 
Brugada syndrome. These 3 patterns may be observed 
spontaneously in serial ECG tracings from the same 
patient or after the introduction of specific drugs.3 
Electrocardiography Manisfestation
A slight prolongation of the QT interval is sometimes 
observed in association with ST-segment elevation in 
Brugada syndrome. The QT interval is prolonged more 
in the right precordial leads than it is in the left precordial 
leads, presumably because of a preferential prolongation 
of action potential duration in right ventricular epicar-
dium secondary to accentuation of the action potential 
notch. Depolarization abnormalities including prolonga-
tion of P wave duration and PR and QRS intervals, are 
frequently observed, particularly in patients linked to 
SCN5A mutations. PR prolongation likely reflects HV 
conduction delay.4
Ionic Mechanism
It is now well established that a transient outward 
current (Ito)–mediated phase 1, which gives rise to 
a notched appearance of the action potential (AP), is 
more prominent in epicardium than in endocardium of 
the ventricles of many species. Transmural differences 
in the contribution of Ito, first suggested in 1988 on 
the basis of AP data, have now been demonstrated by 
use of whole-cell patch-clamp techniques in canine, 
feline, rabbit, rat, and human ventricular myocytes. 
Recent studies also indicate the presence of a much 
larger Ito-mediated notch in right versus left canine 
ventricular epicardium.14,15
The presence of a prominent AP notch in epicar-
dium but not endocardium causes a transmural voltage 
gradient during ventricular activation that has been 
shown to underlie the J-wave and J-point elevation in 
the ECG. The presence of a prominent Ito-mediated 
notch also predisposes canine ventricular epicardium 
to all-or-none repolarization under a variety of condi-
tions, including ischemia. Loss of the AP dome (pla-
teau) in epicardium but not endocardium produces a 
Figure 1. Precordial leads of patient with Brugada syndrome (BS) Three types of SCG feature (type 1, type 2, and 
type 3) are documentred in patient with BS. Arrow indicate the J-wave. (taken from 13)
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Figure 2. Normal relation between right ventricular epicardial, 
endocardial, and M cell action potential and its relevance with 
precordial ECG (taken from 7)
potential notch. A further shift in the balance of current 
leads to loss of the action potential dome and marked 
abbreviation of the epicardial response. The dome fails to 
develop because the outward currents flowing at the end 
of phase 1 overwhelm the inward currents that normally 
give rise to the secondary upstroke and action potential 
plateau.7 When phase 1 reaches approximately −30 mV, 
all-or-none repolarization of the action potential ensues 
leading to loss of the dome as the outward currents 
overwhelm the inward currents.12
Under normal conditions, the J wave is relatively 
small, in large part reflecting the left ventricular ac-
tion potential notch, since that of the right ventricular 
epicardium is usually buried in the QRS. The ST seg-
ment is isoelectric because of the absence of transmural 
voltage gradients at the level of the action potential 
plateau .Accentuation of the right ventricular notch 
under pathophysiological conditions is attended by 
exaggeration of transmural voltage gradients and thus 
exaggeration of the J wave or J point elevation and/or 
the appearance of a saddleback configuration of the 
repolarization waves . The development of a prominent 
J wave can also be construed as ST segment elevation. 
Under these conditions, the T wave remains positive 
because epicardial repolarization precedes repolariza-
tion of the cells in the M and endocardial regions. 
Further accentuation of the notch may be accompanied 
by prolongation of the epicardial action potential such 
that the direction of repolarization across the right 
ventricular wall and transmural voltage gradients are re-
versed, thus leading to the development of a coved-type 
of ST segment elevation and inversion of the T wave 
, typically observed in the ECG of Brugada patients. 
A delay in epicardial activation may also contribute to 
inversion of the T wave.7 (Figure 3)
It is interesting to note that although the typical 
Brugada morphology is present in the substrate for 
reentry is not. A further shift in the balance of cur-
rent, leads to loss of the action potential dome at some 
epicardial sites, which would manifest in the ECG as 
a further ST segment elevation. The loss of the action 
potential dome in epicardium but not endocardium 
results in the development of a marked transmural 
dispersion of repolarization and refractoriness, re-
sponsible for the development of a vulnerable window 
during which a premature impulse or extrasystole can 
induce a reentrant arrhythmia. Because loss of the ac-
tion potential dome in the epicardium is generally not 
spatially uniform, we see the development of a striking 
epicardial dispersion of repolarization.7
voltage gradient during ventricular repolarization that 
is thought to underlie elevation of the ST segment, 
similar to that found in patients with the Brugada 
syndrome. In isolated sheets of canine right ventricular 
(RV) epicardium, heterogeneous loss of the AP dome 
has been shown to induce a marked increase in disper-
sion of repolarization as well as phase 2 reentry, which 
is responsible for the closely coupled extrasystole that 
initiates VT.16,17 (Figure 2)
The cellular basis for the Brugada syndrome is 
thought to be due to an outward shift in the ionic 
current active during phase 1 of the right ventricular 
epicardial action potential.18 A rebalancing of the cur-
rents contributing to the early phases of the action 
potential can accentuate the action potential notch or 
lead to all-or-none repolarization at the end of phase 1, 
causing loss of the epicardial action potential dome and 
marked abbreviation of the action potential at that site. 
A variety of pathophysiological conditions (e.g. ischae-
mia, metabolic inhibition, hypothermia, pressure) and 
some pharmacological interventions are known to effect 
these changes in canine and feline ventricular cells in 
which Ito is prominent. Under these pathophysiologi-
cal conditions or in response to agents that reduce INa 
or ICa or agents that activate IK-ATP or augment IKr, 
ICl(Ca) or Ito, canine ventricular epicardial cells exhibit 
an accentuation of the spike and dome morphology of 
the action potential, resulting in a delay in the develop-
ment of the dome, secondary to widening of the action 
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Conduction of the action potential dome from 
sites at which it is maintained to sites at which it is 
lost causes local reexcitation via a phase 2 reentry 
mechanism, leading to the development of a closely 
coupled extrasystole, capable of triggering circus 
movement reentry The phase 2 reentrant beat fuses 
with the negative T wave of the basic response. Be-
cause the extrasystole originates in the epicardium the 
QRS is largely comprised of a Q wave, which serves 
to accentuate the negative deflection of the inverted 
T wave, thus giving the ECG a more symmetrical 
appearance. This morphology is often observed in the 
clinic preceding the onset of polymorphic ventricular 
tachycardia.18,19 
The influence of the autonomic nervous system 
on STsegment elevation in patients with Brugada 
syndrome is well established.2,3 An increase in vagal 
activity is known to cause an ST-segment elevation in 
the right precordial leads (V1 through V3), whereas 
sympathetic agonists normalize the ST segment. In the 
wedge, acetylcholine (ACh, 1 to 5 μmol/L) depressed 
the AP plateau in RV epicardium but not endocar-
dium in 3 of 5 preparations, leading to an ST-segment 
elevation.4
Diagnosis
Brugada syndrome is definitively diagnosed when a 
type 1 ST-segment elevation is observed in >1 right 
precordial lead (V1 to V3) in the presence or absence 
of a sodium channel– blocking agent, and in conjunc-
tion with one of the following: documented ventricular 
fibrillation (VF), polymorphic ventricular tachycardia 
(VT), a family history of sudden cardiac death at <45 
years old, coved-type ECGs in family members, induc-
ibility of VT with programmed electrical
stimulation, syncope, or nocturnal agonal respira-
tion. The ECG manifestations of the Brugada syn-
drome, when concealed, can be unmasked primarily by 
sodium channel blockers but also during a febrile state 
or with vagotonic agents. Drug challenge generally is 
not performed in asymptomatic patients displaying 
the type 1 ECG under baseline conditions because 
the additional diagnostic value is considered to be 
limited, the added prognostic value is not clear, and 
the test is not without risk for provoking arrhythmic 
events.20,21
Importantly, confounding factor or factors that 
could account for the ECG abnormality or syncope 
should be carefully excluded, including atypical right 
bundle-branch block, left ventricular hypertrophy, 
early repolarization, acute pericarditis, acute myo-
cardial ischemia or infarction, pulmonary embolism, 
Prinzmetal angina, dissecting aortic aneurysm, various 
central and autonomic nervous system abnormalities, 
Duchenne muscular dystrophy, thiamin deficiency, 
hyperkalemia hypercalcemia, arrhythmogenic right 
ventricular dysplasia/cardiomyopathy, pectus excava-
tum,  hypothermia, and mechanical compression of 
the right ventricular outflow tract (RVOT) as occurs 
in mediastinal tumor or hemopericardium.4
Type 2 and type 3 ECG are not diagnostic of 
the Brugada syndrome. These 3 patterns may be 
Figure 3. Mechanism of ST-elevation an upright and inverted T in Brugada syn-
drome (taken from 7)
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 observed spontaneously in serial ECG tracings from 
the same patient or after the introduction of specific 
drugs. The diagnosis of Brugada syndrome is also 
considered positive when a type 2 (saddleback pat-
tern) or type 3 ST-segment elevation is observed in 
>1 right precordial lead under baseline conditions 
and conversion to the diagnostic type 1 pattern oc-
curs after sodium channel blocker administration (ST-
segment elevation should be ≥ 2 mm). One or more 
of the clinical criteria described above also should be 
present. Drug-induced conversion of type 3 to type 2 
ST-segment elevation is considered inconclusive for a 
diagnosis of Brugada syndrome.7
Placement of the right precordial leads in a supe-
rior position (up to the second intercostal space above 
normal) can increase the sensitivity of the ECG for 
detecting the Brugada phenotype in some patients, 
both in the presence or absence of a drug challenge 
.22,23 Although previous reports suggested that none 
of the control patients displayed type 1 ST elevation 
when the V1 to V3 leads were displaced upward, a 
prospective study with a larger number of controls will 
be required to exclude the possibility of false-positive 
results via this method.7 (Figure 4)
Some studies demonstrate that patients with the 
concealed form of the disease are at a similar risk for 
ventricular fibrillation and sudden death as those who 
manifest ST-segment elevation and RBBB persistently. 
These findings suggest that the syndrome may be un-
derdiagnosed and that failure to unmask the disease 
may place patients at considerable risk.5
The mechanisms responsible for the electrocar-
diographic actions of class I antiarrhythmia agents in 
patients with Brugada syndrome have been the subject 
of extensive study by Antzelevitch and others. On the 
basis of these studies, the working hypothesis is that 
a strong sodium channel block facilitates the loss of 
the right ventricular epicardial action dome (plateau 
phase) by altering the balance of current at the end of 
phase 1 of the action potential from inward to outward. 
The result is an all or none repolarization of the right 
ventricular epicardial action potential and marked ab-
breviation of the epicardial action potential duration. 
The loss of the dome in right ventricular epicardium 
but not endocardium creates a transmural voltage 
gradient that manifests as an STsegment elevation in 
the right precordial leads of the ECG and a transmural 
dispersion of refractoriness that can serve as the sub-
strate for the development of functional reentry.5
The specificity of sodium channel blockers such 
as flecainide, ajmaline, procainamide, disopyramide, 
propafenone, and pilsicainide to identify patients 
at risk is uncertain. The recommended dosages are 
listed in Table 1. Drug challenge should be performed 
while the patient is continuously monitored (12 lead 
ECG and blood pressure) and with defibrillator and 
advanced coronary life support facilities close at hand. 
Accurate lead position and correct venous access should 
be ascertained. And should be terminated when the 
diagnostic type 1 Brugada ECG develops, the ST seg-
ment in type 2 ECG increases by ≥ 2 mm, premature 
ventricular beats or other arrhythmias develop, or QRS 
widens to ≥130% of baseline.4,5
Monitoring is recommended until the ECG has 
normalized (plasma half-life of flecainide is 20 hours, of 
procainamide is 3 to 4 hours, and ajmaline inactivated 
within a few minutes).
Figure 4. Shift of right precordial leads to 2nd and 3rd 
intercostal space unmasks a type 1 Brugada ECG
(Taken from 12)
Table 1. Drugs Used to Unmask Brugada Syndrome
Drugs Dosage and Administration
Ajmaline 1 mg/kg over 5 min, iv
Flecainide 2 mg/kg over 10 min, iv (400 mg, PO)
Procainamide 10 mg/kg over 10 min, iv
Pilsicainide 1 mg/kg over 10 min, 1v
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Serious ventricular arrhythmias, including ven-
tricular fibrillation (VF), may occur during the test. 
Immediate discontinuation of the drug is required, 
and isoproterenol infusion might be needed to treat 
the arrhythmias (1 to 3 μg/min isoproterenol).4
The greater sensitivity to ajmaline may be attrib-
utable to differences in the effectiveness of the two 
drugs in blocking the sodium channel current INa at 
the doses used. In the case of flecainide and ajmaline, 
INa inhibition reduces inward current, whereas Ito 
inhibition counters this action of the drugs by blocking 
outward current. Ajmaline and flecainide, in addition 
to reducing the peak amplitude of Ito, significantly 
accelerated the decay of the current, causing a marked 
reduction in the total charge contributing to phase 1 of 
the epicardial action potential and the charge available 
to oppose the reduction of Ina. Data suggest the lesser 
effectiveness of flecainide largely results from its more 
potent inhibition of Ito. Differences in INa inhibition 
at the doses used are difficult to completely rule out as 
a contributing factor.24 (Figure 5)
Procainamide is a class IA antiarrhythmic agent 
that displays a more rapid dissociation from the so-
dium channel and consequently a lower level of use-
dependent sodium channel block.
This characteristic of the drug is believed to 
underlie its lesser potency compared with class IC 
agents such as flecainide in unmasking the syndrome. 
In contrast to ajmaline and flecainide, procainamide 
produces no block of Ito at clinically relevant drug 
concentrations.25
Anzelevitch et al, have previously proposed a 
cellular mechanism for the Brugada syndrome in 
which accentuation of the epicardial action potential 
notch and eventual loss of the epicardial action po-
tential dome results in ST segment elevation, phase 
2 reentry, and polymorphic VT/VF.10 The proposed 
mechanism involves a rebalancing of the currents 
available at the end of phase 1 of the epicardial 
action potential. Diminution of inward currents 
(INa and ICa) or enhancement of outward currents 
(Ito, IK-ATP) can result in a slowing of the second 
upstroke of the epicardial action potential, eventu-
ally leading to loss of the action potential dome as 
a consequence of all-or-none repolarization at the 
end of phase 1.
Based on this schema, we hypothesized that com-
bined INa and ICa block would be more effective in 
unmasking the syndrome.27
The ability of combined INa and ICa block to cause 
Figure 5. Left: Precordial leads before (pre) and after (post) ajmaline. Right: ECG before 
(pre) and after (post) flecainide. Induction of ECG changes after the two corresponding 
tests in the same patient is clearly visible
(Taken from 24)
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loss of the epicardial action potential dome and phase 2 
reentry in the canine right ventricular wedge prepara-
tion. High concentrations of terfenadine, in this case 5 
μM, produced an accentuation of the epicardial action 
potential notch following acceleration of the rate from a 
BCL of 800 msec to 400 msec. The dramatic accentua-
tion of the notch was due to the effect of the drug to 
depress the phase 0, augment the magnitude of phase 1, 
and delay the appearance of the second upstroke. The 
electrocardiographic manifestations of these changes in 
action potential characteristics include an elevation of 
J point, augmentation of the J wave, and inversion of 
the T wave.27
Action potential duration at 90 percent repolar-
ization (APD90) was significantly (p<0.05) shorter 
in epicardium than the endocardium in control. In 
the presence of 5 μM terfenadine, APD90 of Epi 2 
was significantly shorter than that of both Epi 1 and 
endocardium (P < 0,001).27
In another series of experiments, we evaluated the 
effects of three sodium channel blockers (ajmaline, 
≤20 μM, flecainide, ≤7.5 μM, and procainamide, 
≤300 μM) traditionally used to unmask the Brugada 
syndrome in the clinic. Phase 2 reentry was observed 
in 1/17 preparations (5.9%) exposed to ajmaline, fle-
cainide, or procainamide compared with 15/20 (75%) 
exposed to terfenadine or the combination of sodium 
channel block with procainamide or ajmaline and 
calcium channel block with verapamil. Polymorphic 
VT/VF was not observed with ajmaline, flecainide, 
or procainamide alone (0/17), but was induced in 
7/20 preparations (35%) exposed to terfenadine or 
sodium channel blockade (procainamide or ajmaline) 
and verapamil.
Sodium channel blockade (procainamide or ajma-
line) and verapamil induced phase 2 reentry
in 3 out of 4 preparations while verapamil alone 
(≤20 μM) induced phase 2 and verapamil induced 
phase 2 reentry in 3 out of 4 preparations while vera-
pamil alone (≤20 μM) induced phase 2 in only 1 out 
of 4 preparations.27
Electrophysiological studies (EPSs) may be helpful 
in risk stratification and in some cases in establishing 
the diagnosis. A complete EPS is recommended in all 
symptomatic patients.
In VF survivors, EPS may be of little or no diag-
nostic value, but may be helpful in providing further 
insight into the predictive value of available diagnostic 
tools. In the absence of data on sensitivity or specific-
ity of any EPS protocol, we suggest a protocol using 
2 stimulation sites (right ventricular apex [RVA] and 
right ventricular outflow tract), at least 3 cycle lengths 
(600, 430, and 330 ms), 1, 2, and 3 extrastimuli, and 
a minimal coupling interval of 200 ms.4
 
Risk Stratification
Identification of patients at risk for sudden death is an 
important goal of investigators worldwide. Brugada et 
al found that patients initially presenting with aborted 
sudden death are at the highest risk for a recurrence 
(69%), whereas those presenting with syncope and a 
spontaneously appearing Brugada ECG sign have a 
recurrence rate of 19%.28,29
Figure 6. Indications for ICD implantation in patients 
with Brugada syndrome. Class I designation indicates clear 
evidence that the procedure or treatment is useful or ef-
fective; Class II, conflicting evidence about usefulness or 
efficacy; Class IIa, weight of evidence is in favor of useful-
ness or efficacy; and Class IIb, usefulness or efficacy is less 
well established. BS indicates Brugada syndrome; NAR, 
nocturnal agonal respiration; and SCD, sudden cardiac 
death (Taken from 12)
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An 8% occurrence of cardiac events was observed 
in initially asymptomatic patients. Among asymptom-
atic patients, those at highest risk displayed the Bru-
gada sign spontaneously; those in whom ST segment 
elevation appeared only after provocation with sodium 
channel blockers appear to be at minimal or no risk 
for arrhythmic events. Brugada patients at highest risk 
are males with  inducible VT/VF and  a spontaneously 
elevated ST segment.12
Brugada et al30 recently reported on 547 indi-
viduals diagnosed with Brugada syndrome and no 
previous cardiac arrest. In 124 patients the abnormal 
electrocardiogram was identified after one or multiple 
episodes of syncope and in 423 individuals during 
routine electrocardiographic screening or during 
study because they were family members of patients 
with the syndrome. Structural disease was ruled out 
in all patients. 
This study, evaluating the clinical outcome of 
the largest population of Brugada patients thus far 
reported, concluded that:
1. A spontaneously abnormal Type I ECG carried a 
7.7-fold higher risk of developing an arrhythmic 
event during a lifetime as compared to individu-
als in whom the electrocardiogram diagnostic of 
Brugada syndrome was evident only after sodium 
channel blocker challenge
2. Male gender is another risk factor for sudden death, 
because males had a 5.5 higher risk of sudden death 
as compared to females
3. Programmed electrical stimulation resulting in 
inducibility of a sustained ventricular arrhythmia 
is the strongest marker of risk, associated with a 
8-fold higher risk of (aborted) sudden death than 
noninducible patients
4. Familial forms of the disease are not associated with 
a worse prognosis than sporadic cases, because a 
positive family history of Brugada syndrome did 
not predict outcome. They found a 27.2% prob-
ability of an event by logistic regression analysis 
in a patient with a spontaneously abnormal ECG, 
a previous history of syncope, and inducible sus-
tained ventricular arrhythmias
Thus, inducibility of ventricular arrhythmias and a 
previous history of syncope are suggested to be markers 
of a poor prognosis in Brugada syndrome. Symptom-
atic patients require protective treatment even when 
they are not inducible. Asymptomatic patients can be 
reassured if they are noninducible.30
Therapy
Currently, an implantable cardioverter defibrillator 
(ICD) is the only proven effective treatment for the 
disease. In a multicenter trial of 690 patients with 
Brugada syndrome, in which 258 individuals received 
an ICD, efficacy of the device in reverting VF and pre-
venting sudden cardiac death was 100%; appropriate 
shocks were delivered in 14, 20, 29, 38, and 52% of 
cases at 1, 2, 3, 4, and 5 years of follow-up, respec-
tively. In the case of initially asymptomatic patients, 
appropriate ICD discharge was delivered in 4, 6, 9, 
17, and 37% at 1, 2, 3, 4, and 5 years of follow-up, 
respectively.31,32
Current recommendations for ICD implantation are 
summarized as follows:
1.  Symptomatic patients displaying the Type 1 Bru-
gada ECG (either spontaneously or after sodium 
channel blockade) who present with aborted 
sudden death should receive an ICD without ad-
ditional need for EPS. Similar patients presenting 
with related symptoms such as syncope, seizure, 
or noctural agonal respiration should also undergo 
ICD implantation after noncardiac causes of these 
symptoms have been carefully ruled out. EPS is 
recommended in symptomatic patients only for 
the assessment of supraventricular arrhythmia.
2.  Asymptomatic patients displaying a Type 1 Bru-
gada ECG (spontaneously or after sodium channel 
block) should undergo EPS if there is a family his-
tory of sudden cardiac death suspected to be due 
to Brugada syndrome. EPS may be justified when 
the family history is negative for sudden cardiac 
death if the Type 1 ECG occurs spontaneously. If 
inducible for ventricular arrhythmia, the patient 
should receive an ICD. Asymptomatic patients 
who have no family history and who develop a 
Type I ECG only after sodium channel blockade 
should be closely followed up. 
Although there is no room for discussion re-
garding the excellent and uniform efficacy of ICDs 
for terminating VF, the effect is confined to the 
termination of VF, and ICDs cannot contribute to 
the prevention of VF. Therefore, there are some con-
cerns regarding ICD therapy. The first is electrical 
storm associated with VF or polymorphic ventricular 
tachycardia, which is defined as frequent appropriate 
ICD shock deliveries for ventricular tachyarrhyth-
mias of >3 times over 24 hours. Chalvidan et al.33, 
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have been shown to be ineffective.36 Class IC antiar-
rhythmic drugs (eg, flecainide and propafenone) and 
class IA agents (eg, procainamide) are contraindicated 
for reasons enumerated previously. Specific class IA 
agents such as quinidine and tedisamil, however, may 
exert a therapeutic action because of their Ito-blocking 
properties. Because the presence of a prominent 
transient outward current, Ito, in the right ventricle 
is at the heart of the mechanism underlying Brugada 
syndrome, any agent that inhibits this current may be 
protective. Cardioselective and Ito-specific blockers are 
not available. The only agent on the US market with 
significant Ito-blocking properties is quinidine. It is for 
this reason that it was suggested that this agent may be 
of therapeutic value in Brugada syndrome.37 Studies 
have shown quinidine to be effective in restoring the 
epicardial action potential dome, thus normalizing 
the ST segment and preventing phase 2 reentry and 
reported a patient who suffered from incessant VF 
episodes (electrical storm) and became near-fatal, 
but subsequently fully recovered. 
The second is ICD related complications including 
lead dislodgment, inappropriate shock delivery, infec-
tion requiring ICD removal and so on.34,35 
The third is the indication of ICDs for infant cases 
of Brugada syndrome, in which the size of the ICD is 
too large for implantation.34,35
A new therapy other than ICD implantation to 
overcome these concerns seems to be urgent.
The pharmacological approach to therapy, based 
on experimental data, has been tailored to a rebalanc-
ing of currents that are active during the early phases 
of the epicardial action potential in the right ventricle 
to reduce the magnitude of the action potential notch, 
restore the action potential dome, or both Antiar-
rhythmic agents such as amiodarone and β-blockers 
Figure 7. A few days after oral administration of quinidine bisulfate (1500 mg/day, serum 
quinidine level 2.6 mg/L), ST-segment elevation is attenuated displaying a nonspecific (neither 
Type 1-3 Brugada ECG) abnormal pattern in the right precordial leads
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polymorphic VT in experimental models of Brugada 
syndrome. Clinical  evidence of the effectiveness of 
quinidine in normalizing ST-segment elevation in 
patients with Brugada syndrome has been reported (see 
Figure 1) although clinical trials designed to assess the 
efficacy of this agent are limited.38 Relatively high doses 
of quinidine are recommended (1200 to 1500 mg/d). 
Agents that boost the L-type calcium current, such as 
isoproterenol,10 may be useful as well. Both types of 
agents (Ito blocker and agents that augment ICa) have 
been shown to be effective in normalizing ST-segment 
elevation in patients with Brugada syndrome and in 
controlling “electrical storms,” particularly in children. 
(Figure 7)
The most recent addition to the pharmacological 
armamentarium is a phosphodiesterase III inhibitor, 
cilostazol, 39 which normalizes the ST segment most 
likely by augmenting the calcium current (ICa), as well 
as by reducing Ito secondary to an increase in heart 
rate. Finally, an experimental antiarrhythmic agent, 
tedisamil, with potent action to block Ito among other 
outward currents has been suggested as a therapeutic 
candidate.10 Tedisamil may be more potent than 
quinidine because it lacks the relatively strong inward 
current–blocking actions of quinidine. The develop-
ment of a cardioselective and Ito-specific blocker would 
be a most welcome addition to the limited therapeu-
tic armamentarium available to combat this disease. 
Appropriate clinical trials are needed to establish the 
effectiveness of all of the above pharmacological agents 
as well as the possible role of pacemakers in some forms 
of the disease.
Summary
1. The syndrome is estimated to be responsible for at 
least 4% of all sudden deaths and at least 20% of 
sudden deaths in patients with structurally normal 
hearts.
2. The electrocardiographic signature of the syndrome 
is dynamic and often concealed. Normalization of 
the ECG signature of this syndrome by whatever 
mechanism may lead to an underestimation of 
the prevalence of the disease, thus placing some 
patients at risk.
3. Diagnose of Brugada syndrome is the presence 
of type 1 ST-segment elevation  observed in >1 
right precordial lead (V1 to V3) in the used or 
absence of a sodium channel– blocking agent, and 
in conjunction with one of the following: docu-
mented ventricular fibrillation (VF), polymorphic 
ventricular tachycardia (VT), a family history of 
sudden cardiac death at <45 years old, coved-type 
ECGs in family members, inducibility of VT with 
programmed electrical stimulation, syncope, or 
nocturnal agonal respiration.
4. The ECG manifestations of the Brugada syn-
drome, when concealed, can be unmasked pri-
marily by sodium channel blockers and calcium 
channel blocker but also during a febrile state or 
with vagotonic agents.
5. Implantable cardioverter defibrillator (ICD) is the 
only proven effective treatment for the disease. 
Because of its limitation, a new therapy other than 
ICD implantation to overcome these concerns 
seems to be urgent (pharmacotherapy, pacing 
therapy)
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